# Myeloid cells as regulators of systemic autoimmunity

September 29, 2014

Trine N. Jørgensen, Ph.D. Asst. Staff, Lerner Research Institute, Cleveland Clinic Asst. Prof., Cleveland Clinic College of Medicine at Case Western Reserve University

# **Autoimmune Disorders**



# Systemic Lupus Erythematosus

Estimated 1.5 million patients in USA

Diagnosis occur most often between the ages of 15 and 45.

Diagnosis based on multiple criteria

Much more prevalent in women than in men

Etiology unknown, but dependent on both genetic, environmental and hormonal factors







### Immunosuppressive neutrophil-like cells protect male lupus-prone mice from disease development

#### **Abhishek Trigunaite**

Evan Der

Ayesha Khan









Sanjay Varikuti E

Elena Gonzalez



**Anne Song** 

Justin Jones



Joana Dimo



### New Zealand Hybrid Mice



New Zealand Hybrid mice (NZB x NZW)F1 are characterized by the spontaneous development of lupus-like disease including lymphadenopathy and splenomegaly, spontaneous presence of hyperactive B cells, elevated levels of anti-nuclear autoantibodies, immune complex formation, glomerulonephritis and death from kidney failure.



# Male BWF1 mice develop disease with a delayed onset and reduced incidence



### Neutrophil-like cells are elevated in protected lupus-prone male (NZB x NZW)F1 mice



Cleveland Clinic

Trigunaite et al, Arthritis Rheum. 2013

### Neutrophil-like Gr1<sup>+</sup> cells are regulated by Testosterone *in vivo*



Are neutrophil-like cells in male lupusprone (NZB x NZW)F1 mice immunosuppressive?



# Gr1<sup>+</sup> cell subsets suppress B and T cell activation and differentiation *in vitro*



#### As the mice age, female Gr1<sup>+</sup> cell subsets lose their suppressive capacity



### What is the function of Gr1+ cells *in vivo* in (NZB x NZW)F1 mice?



# Gr1-expressing cell subsets suppress spontaneous and induced antibody-production *in vivo*



#### Gr1-expressing cell subsets fail to suppress TI-antibody responses *in vivo*



Der et al, J. Immunol. 2014.

# Germinal center formation and the regulation of T-dependent immune responses





Ma et al. JEM 2012

# Gr1-expressing cells suppress $T_{FH}$ cell differentiation and germinal center formation



Der et al, J. Immunol. 2014.

# What effector functions do neutrophillike cells utilize to suppress antibody production in male lupus-prone (NZB x NZW)F1 mice?

# Female Gr1<sup>hi</sup>CD11b<sup>+</sup> cells use NO/ROS to suppress B cell differentiation



#### Calgranulin B (S100a9) can act as an immunosuppressive molecule in cancer – and is overexpressed by male Gr1<sup>+</sup> cells



#### S100a9-deficient Gr1<sup>high</sup>CD11b<sup>+</sup> cells cannot suppress B cell differentiation *in vitro* and *in vivo*





### Summary 1

- 1. Gr1<sup>+</sup> cells are elevated in male mice
- 2. Gr1<sup>+</sup> cells are regulated by testosterone
- 3. <u>Gr1<sup>high</sup>CD11b<sup>+</sup> cells</u> suppress B cell differentiation
- 4. <u>Gr1<sup>low</sup>CD11b<sup>+</sup> cells</u> suppress T cell proliferation/differentiation
- 5. Depletion of Gr1<sup>+</sup> cells results in elevated AAb production in male, but not female, lupus-prone mice
- Female Gr1<sup>high</sup>CD11b<sup>+</sup> cells use ROS/NO to suppress B cell differentiation *in vitro*
- 7. Male Gr1<sup>high</sup>CD11b<sup>+</sup> cells appear to use S100a9 as their mechanism of suppression *in vitro*
- 8. S100a9<sup>-/-</sup> lupus-prone male mice produce increased levels of Ab *in vivo*

Cleveland Clinic

#### Working Model



**Cleveland Clinic** 

Der et al, JCCI 2014

Jorgensen lab <u>Current members</u> Abhishek Trigunaite, M.Sc. Laura Davison, B.S. Joana Dimo Lauren Liegl Andres Alberto

Past members Angela Johnson, Ph.D. Natalia Gilitay, Ph.D. Ayesha Khan, B.S. Evan Der, B.S. Srita Chakka, B.S. Reut Gurion, M.D. Anne Song, B.S. Chairut Vareechon, M.Sc. Divya Khosla, M.Sc. Di Sun, M.D. Serena MacDonald, B.S. Nodoka Sakurai, M.D. Ami Saraiya, M.D. Thomas Carroll



The Official Lab T-shirt



**Collaborations** Dr. Xiaoxia Li, CCF

Dr. Damir Janigro, CCF Phil Iffland III

Dr. Philippa Marrack, NJRMC Alexandria David Megan MacLeod, Ph.D.

Dr. Loren Erickson, UVA

**Previous Mentor** Dr. Brian Kotzin, Amgen

Funding Sources NIAID Department of Defense Sjogrens Syndrome Foundation